SCHEMBL6538508

SCHEMBL6538508

COc1ccc(-c2nc(N)c(Cl)cc2-c2ccc(=O)n(C(C)C)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 7/20 0.43
ABL1 P00519 3/20 0.43
HCK P08631 2/20 0.43
EGFR P00533 2/20 0.43
PIK3CD O00329 1/20 0.43
KDR P35968 1/20 0.43
PIK3CA P42336 1/20 0.43
PIK3CB P42338 1/20 0.43
MTOR P42345 1/20 0.43
PIK3CG P48736 1/20 0.43
EPHB4 P54760 1/20 0.43
PRKDC P78527 1/20 0.43
PI4KB Q9UBF8 1/20 0.43
LCK P06239 1/20 0.41
EPHA3 P29320 1/20 0.41
CSK P41240 1/20 0.41
FGFR1 P11362 4/20 0.40
FGFR2 P21802 4/20 0.40
FGFR3 P22607 4/20 0.40
CDK4 P11802 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6539151 0.90 ABL1 (0.48) SRCABL1HCKEGFRPIK3CD
SCHEMBL6538377 0.88 SRC (0.41) SRCABL1HCKEGFRPIK3CD
SCHEMBL6539283 0.87 ADORA2A (0.42) SRCABL1HCKEGFRPIK3CD
SCHEMBL6538926 0.87 POLB (0.39) SRCABL1HCKEGFRPIK3CD
SCHEMBL6539117 0.82 PDE1A (0.43) SRCABL1HCKEGFRPIK3CD
SCHEMBL6538300 0.81 PIK3CG (0.46) SRCABL1HCKEGFRPIK3CD
SCHEMBL6133595 0.81 KMT2A (0.58) SRCABL1HCKEGFRPIK3CD
SCHEMBL6539142 0.79 ADORA2A (0.36) SRCFGFR1FGFR2FGFR3POLB
SCHEMBL6538407 0.78 CA2 (0.38) SRCABL1HCKEGFRPIK3CD
SCHEMBL6539332 0.78 LMNA (0.35) SRCABL1HCKEGFRPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067955-A1 Pyridazinone compound and pharmaceutical use thereof ADORA1, ADORA2A, P2RX5 SRC 3470/4885ABL1 3080/4885HCK 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.